2-benzyl-2-azabicyclo[2.2.1]heptan-7-amine | 951393-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-benzyl-2-azabicyclo[2.2.1]heptan-7-amine
• 英文别名: (1SR,4SR,7SR)-2-benzyl-2-azabicyclo[2.2.1]heptan-7-amine
• CAS: 951393-79-6
• 化学式: C₁₃H₁₈N₂
• mdl: MFCD20441687
• 分子量: 202.299
• InChiKey: RLVKNSFGRHNZJI-UHFFFAOYSA-N

物化性质

• 沸点：
  298.9±23.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(2-benzyl-2-azabicyclo[2.2.1]hept-7-yl)-1H-isoindole-1,3(2H)-dione 在 肼 、 盐酸 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 2-benzyl-2-azabicyclo[2.2.1]heptan-7-amine
  参考文献：
  名称：

  WO2007/110782

  摘要：

  公开号：

文献信息

• [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2015160634A1

  公开（公告）日：2015-10-22

  In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  在其多种实施方式中，本发明提供了一类新型苯甲酰胺化合物，其由式（I）表示，或其药学上可接受的盐或溶剂，或包含一种或多种所述化合物或其药学上可接受的盐或溶剂的药物组合物，以及使用所述化合物或其药学上可接受的盐或溶剂来治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。
• BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
  申请人：Lampe John W.

  公开号：US20110144150A1

  公开（公告）日：2011-06-16

  The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema.

  本发明涉及一种合成的桥接双环化合物，该化合物是rho相关蛋白激酶的抑制剂。本发明还涉及包括这些化合物和药用可接受载体的药物组合物。此外，本发明还涉及一种预防或治疗与细胞骨架重组相关的疾病或症状的方法。该方法包括向受试者施用一定量的具有治疗作用的公式I的Rho激酶抑制剂化合物，其中该量有效地影响肌动蛋白互作，例如，通过导致细胞松弛和细胞-基质粘附的改变。在一种实施方式中，该方法治疗增加的眼内压，如原发性开角青光眼。在另一种实施方式中，该方法治疗与肺部细胞过度增殖、重塑、炎症、血管收缩、支气管收缩、气道高反应性和水肿相关的疾病或症状。
• BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND USE
  申请人：Lampe John W.

  公开号：US20130281485A1

  公开（公告）日：2013-10-24

  The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema.

  本发明涉及一种合成的桥接双环化合物，它们是rho相关蛋白激酶的抑制剂。本发明还涉及包含这种化合物和药用载体的制药组合物。此外，本发明还涉及一种预防或治疗与细胞骨架重组相关的疾病或病症的方法。该方法包括向受试者施用一种公式I的Rho激酶抑制化合物的治疗有效量，其中该量对影响肌动蛋白相互作用有效，例如通过导致细胞松弛和细胞-基质附着的变化。在一种实施方式中，该方法治疗增加的眼压，例如原发性开角型青光眼。在另一种实施方式中，该方法治疗与过度细胞增殖、重塑、炎症、血管收缩、支气管收缩、气道高反应性和水肿相关的肺部疾病或病症。
• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Kumar Naresh

  公开号：US20090137623A1

  公开（公告）日：2009-05-28

  The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.

  本发明涉及毒蕈碱受体调节剂，具体地，涉及式（I）的7-氧代-2-氮杂双环[2.2.1]庚烷，它们可用于治疗各种疾病和病症，例如阿尔茨海默病、青光眼、精神病，特别是精神分裂症或类精神分裂症，躁狂症、疼痛、双相情感障碍、抑郁症、睡眠障碍、癫痫、胃肠动力障碍、尿失禁和认知增强。
• FACTOR IXA INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3131896B1

  公开（公告）日：2019-01-30